Argus analyst Jasper Hellweg raised the firm’s price target on Regeneron to $920 from $825 and keeps a Buy rating on the shares. The analyst is positive on the company’s continued pipeline advancements and expects Regeneron to benefit from positive developments over the next 12 months, including the FDA approvals for Eylea HD Injection 8 mg and for Veopoz. At 20-times projected current-year earnings, the stock’s valuation is also “well below” the peer average of 26-times, the firm tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on REGN:
- Regeneron initiated with a Hold at WestPark Capital
- White House imposes price limits on Covid drug in Regeneron deal, STATNews says
- Regeneron Announces Updates to Board of Directors
- Regeneron CFO Robert Landry to retire, Christopher Fenimore to succeed
- Regeneron Provides Update on Planned Chief Financial Officer Transition
Questions or Comments about the article? Write to editor@tipranks.com